The Efficacy of Combination Treatment with Injectable Testosterone Undecanoate and Daily Tadalafil for Erectile Dysfunction with Testosterone Deficiency Syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Min Gu | - |
dc.contributor.author | Yeo, Jeong Kyun | - |
dc.contributor.author | Cho, Dae-Yeon | - |
dc.contributor.author | Kim, Jin Wook | - |
dc.contributor.author | Kim, Jong Wook | - |
dc.contributor.author | Oh, Mi Mi | - |
dc.contributor.author | Kim, Je Jong | - |
dc.contributor.author | Moon, Du Geon | - |
dc.date.available | 2019-03-08T17:40:46Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 1743-6095 | - |
dc.identifier.issn | 1743-6109 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9704 | - |
dc.description.abstract | IntroductionBoth testosterone therapy and chronic treatment with phosphodiesterase type 5 inhibitors (PDE5Is) have positive effects on the histology of penile corpora and erectile function. However, few clinical studies have evaluated the efficacy of combination therapy with both testosterone replacement and chronic PDE5Is. AimThis study was designed to evaluate the efficacy and safety of combination treatment with long-acting injectable testosterone undecanoate (TU) and a once-daily tadalafil 5mg for erectile dysfunction with testosterone deficiency syndrome. MethodsSixty patients were consecutively enrolled and followed for 36 weeks. Thirty patients were randomly assigned to group I and received 1,000mg of parenteral TU on day 1, followed by additional injections at weeks 6 and 18 with on-demand tadalafil 10-20mg during the 30 weeks of treatment. The remaining 30 patients received the same dose and schedule of TU as group I, and were prescribed once-daily tadalafil 5mg during 30 weeks. Main Outcome MeasuresSerological tests were performed, and the International Index of Erectile Function (IIEF), Aging Males' Symptoms (AMS) questionnaires, and Global Assessment Question (GAQ) were administered to the patients. ResultsTotal IIEF and AMS scores were significantly improved during the 30 weeks of treatment in both groups. When IIEF scores were compared between the two groups, group II showed better symptom scores than group I at weeks 6 and 30. A similar pattern was observed when comparing AMS scores between the groups. At week 36, changes in IIEF and AMS scores that indicated worsened symptoms compared with week 30 were observed in both groups; group II showed better symptom scores than group I. On the GAQ, the ratio of patients reporting improvement in erectile function was significantly higher in group II than group I. ConclusionsThe combination of long-acting injectable TU and once-daily tadalafil 5mg produced a significant improvement in erectile function. Moreover, the improvement in erectile function was well maintained, even after the cessation of treatment. Park MG, Yeo JK, Cho D-Y, Kim JW, Kim JW, Oh MM, Kim JJ, and Moon DG. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med 2015;12:966-974. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | The Efficacy of Combination Treatment with Injectable Testosterone Undecanoate and Daily Tadalafil for Erectile Dysfunction with Testosterone Deficiency Syndrome | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/jsm.12842 | - |
dc.identifier.bibliographicCitation | JOURNAL OF SEXUAL MEDICINE, v.12, no.4, pp 966 - 974 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000352622100011 | - |
dc.identifier.scopusid | 2-s2.0-84926419897 | - |
dc.citation.endPage | 974 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 966 | - |
dc.citation.title | JOURNAL OF SEXUAL MEDICINE | - |
dc.citation.volume | 12 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Hypogonadism | - |
dc.subject.keywordAuthor | Tadalafil | - |
dc.subject.keywordAuthor | Injectable Testosterone Undecanoate | - |
dc.subject.keywordAuthor | Erectile Dysfunction | - |
dc.subject.keywordPlus | ON-DEMAND TADALAFIL | - |
dc.subject.keywordPlus | AGED DIABETIC-RATS | - |
dc.subject.keywordPlus | HYPOGONADAL MEN | - |
dc.subject.keywordPlus | A-DAY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | REPLACEMENT | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SILDENAFIL/TADALAFIL | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | STIMULATION | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.